ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2020, Vol. 12 ›› Issue (3): 233-236.doi: 10.3969/j.issn.1674-3865.2020.03.014

• 临床研究 • 上一篇    下一篇

丙种球蛋白辅助治疗儿童难治性肺炎支原体肺炎的临床疗效

方俊梅,包晓珍   

  1. 322100 浙江 东阳,东阳市妇幼保健院儿科
  • 出版日期:2020-06-25 发布日期:2021-05-17
  • 通讯作者: 方俊梅,E-mail:fjm1779@163.com
  • 作者简介:方俊梅(1973-),女,主任医师。研究方向:小儿咳喘、小儿危重症急救
  • 基金资助:
    浙江省医学会临床科研基金项目(2017 ZYCA108)

Clinical effect of immunoglobulin in the treatment of refractory Mycoplasma pneumoniae pneumonia in children

  • Online:2020-06-25 Published:2021-05-17

摘要: 目的 观察静脉注射应用丙种球蛋白辅助治疗儿童难治性肺炎支原体肺炎(RMPP)的临床疗效。 方法 选择2018年1月至2019年5月我院收治住院的RMPP患儿80例,随机分为观察组和对照组各40例。所有试验对象都在阿奇霉素序贯抗感染加用糖皮质激素治疗为基础,观察组加用静脉注射丙种球蛋白,对照组未使用丙种球蛋白。对比两组患儿的临床症状恢复时间、影像学恢复时间,住院时间以及两组治疗前后总的临床疗效。 结果 观察组临床症状体征恢复时间、影像学恢复时间,住院时间均低于对照组,差异有统计学意义(P<0.05);同时观察组治疗2周后总有效率为85.0%(34/40),显著高于对照组50.0%(20/40),差异有统计学意义(P<0.05)。 结论 应用丙种球蛋白辅助治疗后可加快儿童RMPP临床症状体征的恢复,加快影像学的恢复,缩短了总的住院时间,提高了儿童RMPP总的临床疗效,减少并发症的发生率。

关键词: 难治性肺炎支原体肺炎, 丙种球蛋白, 儿童

Abstract: Objective To observe the clinical effect of intravenous injection of immunoglobulin in the treatment of refractory Mycoplasma pneumoniae pneumonia (RMPP) in children. Methods A total of 80 RMPP children treated in our hospital from Jan. 2018 to May 2019 were randomly divided into two groups: 40 children in observation group and 40 in control group. All children in the two groups were given azithromycin sequential antiinfection treatment plus corticosteroid therapy; the observation group also received intravenous injection of immunoglobulin. The recovery time of clinical symptoms and signs, the recovery time of imaging symptoms, length of hospital stay and the clinical effect after treatment were compared between the two groups. Results The recovery time of clinical symptoms and signs, the recovery time of imaging symptoms and hospitalization time in the treatment group were shorter than those in the control group with statistically significant differences(P<0.05). Meanwhile, the total effective rate of the experimental group (85.0%,34/40) was significantly higher than that of the control group(50.0%,20/40) after 2 weeks of treatment, and the difference was statistically significant(P<0.05). Conclusion The application of immunoglobulin can accelerate the recovery of clinical symptoms and signs of RMPP children, accelerate the recovery of imaging symptoms, shorten the total hospital stay, improve the overall clinical effect on children with refractory Mycoplasma pneumoniae pneumonia, and reduce the incidence of complications.

Key words: Refractory Mycoplasma pneumoniae pneumonia, Immunoglobulin, Children